The acute hepatic porphyrias and their neurologic syndromes;DIE AKUTEN HEPATISCHEN PORPHYRIEN UND IHRE NEUROLOGISCHEN SYNDROME

Schweizerische Medizinische Wochenschrift

Volumn 126, Issue 1-2, 1996, Pages 6-14

  Bont, A ^a,c   Steck, A J ^a   Meyer, U A ^b  

^a Neurologische Universitatsklinik Basel   (Switzerland)

^b UNIVERSITY OF BASEL   (Switzerland)

^c FMH Neurologie   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; BROMIDE; CLONAZEPAM; GABAPENTIN; HEME; HEME ARGINATE; VIGABATRIN;

DISEASE CLASSIFICATION; HEPATIC PORPHYRIA; HUMAN; NEUROLOGIC DISEASE; NEUROPATHY; PROGNOSIS; REVIEW; SEIZURE;

ABDOMEN, ACUTE; AUTONOMIC NERVOUS SYSTEM DISEASES; CENTRAL NERVOUS SYSTEM DISEASES; DIETARY CARBOHYDRATES; HUMANS; PORPHYRIAS, HEPATIC; PORPHYRINS; PROGNOSIS; SYNDROME;

EID: 0030068154     PISSN: 00367672     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (45)

1. Kappas A, Sassa S, Anderson KE: The porphyrias, in: Stanbury JB, Weyngaarden JB, Fredrikson DS, Goldstein JL, Broen MS (Hrsg): The metabolic basis of inherited disease. New York: McGraw-Hill, 1989: 1305-1365.
2. Kushner JP: Laboratory diagnosis of the porphyrias [Editorial]. N Engl J Med 1991; 324: 1432-1434.
3. Meyer UA: Porphyrias. In: Braunwald E, Isselbacher KJ, Petersdorf RG, Wilson JD, Martin JB, Fauci AS (Hrsg): Harrison's principles of internal medicine. New York: McGraw-Hill, 1987: 1638-1643.
4. Moore MR: Biochemistry of porphyria. Int J Biochem 1993; 25: 1353-1368.
5. Bloomer JR, Straka JG: Porphyrin metabolism. In: Arias JM, Jakoby WB, Popper H, Schachter D, Shafritz H (Hrsg): The liver: Biology and pathobiology. New York: Raven Press, 1988: 451-466.
6. Kauppinen R, Mustajoki P: Prognosis of acute porphyria: occurrence of acute attacks, precipitating factors and associated diseases. Medecine 1992; 71: 1-13.
7. Tefferi A, Solberg LA, Ellefson RD: Porphyrias: Clinical evaluation and interpretation of laboratory tests. Mayo Clin Proc 1994; 69: 289-290.
8. Gu X-F, de Rooij F, Voortman G, Te Velde K, Nordmann Y, Grandchamp B: High frequency of mutations in exon 10 of the porphobilinogen deaminase gene in patients with a CRIM-positive subtype of acute intermittent porphyria. Am J Hum Genet 1992; 51: 660-665.
9. Chen C-H, Astrin KH, Lee G, Anderson KE, Desnick RJ: Acute intermittent porphyria: identification and expression of exonic mutations in the hydroxymethylbilane synthase gene. 1994; 94: 1927-1937.
10. Windebank AJ, Bonkowsky HL: Porphyric neuropathy. In: Dyck PJ, Thomas PK, Griffin JW, Low PA, Poduslo JF (Hrsg): Peripheral neuropathy. Philadelphia: WB Saunders, 1993: 1161-1168.
11. Logan GM, Weimer MK, Ellefson M, Pierach CA, Bloomer JR: Bile porphyrin analysis in the evaluation of variegata porphyria. N Engl J Med 1991; 324: 1408-1411.
12. Bonkowsky HL, Schady W: Neurologic manifestations of acute prophyria. Sem Liver Dis 1982; 2: 108-124.
13. Schaumburg HH, Berger AR, Thomas PK: Clinical features of acute intermittent porphyria. In: Schaumburg HH, Berger AR, Thomas PK (Hrsg): Disorders of peripheral nerves. Philadelphia: FA Davis Co, 1992: 168-171.
14. Schley G, Anlauf M, Bock KD: Akute intermittierende Porphyrie. Beobachtungen bei 12 Fällen mit 49 akuten Schüben. Med Klin 1976; 71: 1891-1897.
15. Becker DM, Kramer S: The neurological manifestations of porphyrias. Medicine 1977; 56: 411-423.
16. Goldstein NP, Martin WJ, Brunsting LA, Kirby TJ: Blindness of cerebral origin in porphyria: report of case. Mayo Clin Proc 1957; 32: 82-88.
17. Lai CW, Hung T, Lin WSJ: Blindness of cerebral origin in acute intermittent porphyria. Report of a case and postmortem examination. Arch Neurol 1977; 34: 310-312.
18. Sato M, Tomizaki Y: A case of transient cerebral blindness in acute intermittent porphyria. Folia Ophthalmol Jpn 1992; 4: 1378-1381.
19. Kupferschmidt H, Bont A, Schnorf H, Landis Th, Meier-Abt PJ: Transient cortical blindness and bioccipital ischemic brain lesions in two patients with acute intermittent porphyria. Ann Intern Med 1995; 123: 598-600.
20. Hauser RA, Lacey DM, Knight MR: Hypertensive encephalopathy. Magnetic resonance imaging demonstration of reversible cortical and white matter lesions. Arch Neurol 1988; 45: 1078-1083.
21. Miller DH, Ormerod JE, Gibson A, du Boulay EP, Rudge P, McDonald WJ: MR brain scanning in patients with vasculitis: differentiation from multiple sclerosis. Neuroradiology 1987; 29: 226-231.
22. Kuhn MJ, Shekar PC: A comparative study of magnetic resonance imaging and computed tomography in the evaluation of migraine. Comput Med Imaging Graph 1990; 14: 149-152.
23. Albers JW, Robertson WC, Daube JR: Electrodiagnostic findings in acute porphyric neuropathy. Muscle Nerve 1978; 1: 292-296.
24. Ridley A: The neuropathy of acute intermittent porphyria. Q J Med 1969; 38: 307-333.
25. Hierons R: Changes in the nervous system in acute porphyria. Brain 1957; 80: 176-192.
26. Perlroth MG, Tschudy DP, Marven HS, Berard CW, Zeigel RF et al.: New morphologic and biochemical findings. Am J Med 1966; 41: 149-162.
27. Cavanagh JB, Mellick RS: On the nature of the peripheral nerve lesions associated with acute intermittent porphyria. J Neurol Neurosurg Psychiatry 1965; 28: 320-327.
28. Cavanagh JB, Ridley AR: The nature of the neuropathy complicating acute intermittent porphyria. Lancet 1967/II: 1023-1024.
29. Sweeney VP, Pathak MH, Asbury AK: Acute intermittent porphyria. Increased ALA-synthetase activity during an acute attack. Brain 1970; 93: 369-380.
30. Percy VA, Shanley BC: Studies on haem biosynthesis in rat brain. J Neurochem 1979; 33: 1267-1274.
31. Litman DA, Correia MA: L-Tryptophan: A common denominator of biochemical and neurological events of acute hepatic porphyria? Science 1983; 222: 1031-1033.
32. Moncada S, Higgs A: The L-arginine-nitric oxide pathway. N Engl J Med 1993; 329: 1993-2000.
33. Herrick AL, Mc Coll KE, Moore MR, Cook A: Controlled trial of haem arginate in acute hepatic porphyria. Lancet 1989/I: 1295-1297.
34. Pierach CA: Haem and porphyria attacks. Lancet 1989/II: 213.
35. Mustajoki P, Tenhunen R, Pierach C, Violin L: Heme in the treatment of porphyrias and hematological disorders. Sem Hematol 1989; 26: 1-9.
36. Magnussen CR, Doherty JM, Hess RA, Tschudy DP: Grand mal seizures and acute intermittent porphyria. Neurology 1975; 25: 1121-1125.
37. Larson AW, Wasserstrom WR, Felsher BF, Shih JC: Post-traumatic epilepsy and acute intermittent porphyria: effects of phenytoin, carbamazepin and clonazepan. Neurology 1978; 28: 824-828.
38. Bonkowsky HL, Sinclair PR, Emery S, Sinclair JF: Seizure management in acute hepatic porphyria: risks of valporate and chlonazepam. Neurology 1980; 30: 588-592.
39. Kälviäinen R, Keränen T, Riekkinen PJ: Place of newer antiepileptic drugs in the treatment of epilepsy. Drugs 1993; 46: 1009-1024.
40. Ramsay RE: Clinical efficacy and safety of gabapentin. Neurology 1994; 44 (Suppl. 5): 523-530.
41. Mc Lean MJ: Clinical pharmacokinetics of gabapentin. Neurology 1994; 44 (Suppl. 5): 517-522.
42. Mumford JP, Cannon DJ: Vigabatrin. Epilepsia 1994; 35 (Suppl. 5) 525-528.
43. Krauss GL, Simmons-O'Brien E, Campbell M: Successful treatment of seizures and porphyria with gabapentin. Neurology 1995; 45: 594-595.
44. Stein JA, Tschudy DP: Acute intermittent porphyria. A clinical and biochemical study of 46 patients. Medicine 1970; 49: 1-16.
45. Bosch EP, Pierach CA, Bossenmaier J, Cardinal R, Thorson M: Effect of hematin in porphyric neuropathy. Neurology 1977; 27: 1053-1056.